Welcome to our dedicated page for Arrowhead Pharma news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Pharma stock.
Arrowhead Pharmaceuticals develops and commercializes RNA interference medicines that silence genes associated with intractable diseases. The company’s TRiM™ platform is used to design targeted RNAi therapeutics for tissues including liver, lung, muscle, adipose and central nervous system tissue.
Recurring ARWR news covers REDEMPLO® (plozasiran), an siRNA medicine approved in the United States and Australia as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome. Company updates also address plozasiran data across hypertriglyceridemia, regulatory actions in additional geographies, pricing and market-access strategy, fiscal results, investor events, and clinical or partnering developments involving programs such as ARO-PNPLA3, ARO-INHBE and ARO-ALK7.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported strong fiscal Q2 2025 results, marking significant financial and operational progress. The company posted revenue of $542.7 million, compared to no revenue in Q2 2024, and net income of $370.4 million versus a loss of $125.3 million year-over-year. Following a major licensing deal with Sarepta Therapeutics worth $825 million upfront, Arrowhead is now funded into 2028.
The FDA has accepted the NDA for plozasiran for FCS treatment, with a PDUFA date of November 18, 2025. The company's financial position strengthened with total cash resources reaching $1.1 billion as of March 31, 2025. Additionally, CFO Ken Myszkowski will retire, to be succeeded by Daniel Apel effective May 13, 2025.
[ "Revenue surged to $542.7M in Q2 2025 from zero in Q2 2024", "Net income improved to $370.4M from a loss of $125.3M year-over-year", "Secured $825M upfront from Sarepta deal ($500M cash + $325M equity investment)", "FDA accepted NDA for plozasiran with PDUFA date set", "Cash resources increased to $1.1B, with funding secured through 2028", "Potential for $10B in milestone payments from Sarepta partnership" ]Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced its participation in two major investor conferences in May 2025. The company will present at the BofA Securities 2025 Health Care Conference on May 14, 2025, at 11:20 a.m. PDT, and at the 2025 RBC Capital Markets Global Healthcare conference on May 20, 2025, at 2:35 p.m. EDT. Both presentations will be in a fireside chat format and webcasts will be accessible through the Events and Presentations page in the Investors section of Arrowhead's website.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has scheduled its fiscal 2025 second quarter financial results webcast and conference call for May 12, 2025, at 4:30 p.m. ET. The presentation will cover financial performance for the quarter ended March 31, 2025.
Investors can access the live audio webcast through the Events and Presentations page in the Investors section of the Arrowhead website. A replay option will be available approximately two hours after the call concludes.
For analysts interested in participating in the conference call, registration is required at the provided media server link. Upon registration, participants will receive a personalized PIN code and dial-in number for call access.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a key leadership transition, with Daniel Apel appointed as the new Chief Financial Officer, effective May 13, 2025. He will succeed Ken Myszkowski, who is retiring after 16 years with the company. Myszkowski will remain as an employee adviser to ensure a smooth transition.
Apel joins Arrowhead from Walgreens Boots Alliance, where he served as Global Head of Financial Planning and Analysis (2019-2024). His extensive experience includes nearly 20 years at Bayer, where he held positions as CFO of Bayer U.S. (2016-2019) and CFO of Bayer Canada. The transition comes as Arrowhead prepares for its planned launch of plozasiran this year, pending regulatory approval, marking the company's shift from development to commercial stage.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced the approval of inducement grants for 21 new employees by its Board of Directors on April 3, 2025. The grants, approved under NASDAQ Listing Rule 5635(c)(4), collectively provide up to 34,190 restricted stock units to the new hires. These equity awards are structured outside the company's stockholder-approved equity incentive plans and feature a four-year annual vesting schedule.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced topline results from Part 2 of its Phase 1/2 study of ARO-C3, an RNAi therapeutic targeting complement component 3 (C3) for complement-mediated diseases. The study focused on patients with IgA nephropathy (IgAN).
Key findings from the trial (n=14) include:
- Mean sustained C3 reduction >87% through week 24
- Mean sustained AH50 reduction >76% through week 24
- Mean sustained Wieslab AP reduction >89% through week 24
- Mean reduction in spot UPCR of 41% by week 24, with maximum individual reduction of 89%
The treatment was generally well-tolerated with no serious adverse events reported. The most common side effects were headache, cough, and nasopharyngitis. The duration of effect supports quarterly or less frequent subcutaneous dosing in future studies. Additional results will be presented at a medical meeting in 2025.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) presented preclinical data for two first-in-class RNAi-based therapeutics for obesity treatment: ARO-INHBE and ARO-ALK7. Both candidates target fat storage pathways while potentially preserving lean muscle mass better than current obesity therapies.
Key preclinical results showed:
- ARO-INHBE achieved 19% body weight reduction and 22% fat mass reduction in mice
- ARO-ALK7 demonstrated 39% body weight reduction and 50% fat mass reduction
- Both treatments improved liver fat accumulation
- Combination with tirzepatide showed enhanced benefits
Phase 1/2 clinical trials are underway, with ARO-INHBE dosing initiated in December 2024 and initial data expected by end of 2025. ARO-ALK7 dosing is anticipated to begin in Q2 2025, with preliminary data expected by year-end 2025.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has expanded its 'We'll Get There Soon' campaign on Rare Disease Day with new patient-centric resources for Familial Chylomicronemia Syndrome (FCS). The initiative includes the launch of www.LowerMyTGs.com, a dedicated educational website, and the release of the 'Spotlight on FCS' white paper.
FCS is an ultra-rare genetic disorder affecting 1-13 people per million globally, impairing the body's ability to process triglycerides. Patients typically experience dangerously high triglyceride levels exceeding 880 mg/dL, increasing the risk of acute pancreatitis. Expert guidelines recommend maintaining levels below 500 mg/dL.
The new resources, developed in collaboration with the FCS Foundation, Action FCS, and FH Europe Foundation, provide educational content, patient testimonials, and community connection opportunities. The initiative aims to amplify patient voices and address the underdiagnosis of FCS while supporting those affected by extremely high triglycerides.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) presented preclinical data on ARO-ALK7, its investigational RNAi therapeutic targeting ALK7 for obesity treatment, at the Keystone Symposia on Obesity and Adipose Tissue in February 2025. The company received regulatory clearance to begin a Phase 1/2a clinical trial in New Zealand, with dosing expected in Q2 2025.
Preclinical studies showed dose-dependent reductions in ALK7 mRNA in adipose tissue, with approximately 80% knockdown at 0.3 mg/kg and 91% at 1.5 mg/kg in non-human primates. In diet-induced obese mice, ARO-ALK7 suppressed body weight gain by 40% and reduced fat mass by approximately 50% while preserving lean mass.
Notably, when combined with tirzepatide (a GLP-1/GIP receptor co-agonist), ARO-ALK7 showed additive effects on weight and fat loss while ameliorating tirzepatide's lean mass reduction. The fat loss mechanism involves increased energy expenditure and lipolysis without affecting food intake. Toxicology studies in rats showed the treatment was generally well-tolerated.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported its fiscal 2025 first quarter results, highlighting significant developments. The company secured a major licensing agreement with Sarepta Therapeutics, receiving $825 million upfront ($500M cash, $325M equity investment) plus $250 million over five years, with potential additional payments of $300 million and approximately $10 billion in milestones.
The FDA accepted Arrowhead's NDA for plozasiran for familial chylomicronemia syndrome treatment, with a PDUFA date of November 18, 2025. Phase 3 PALISADE study showed positive results with significant reductions in triglycerides.
Financial results showed revenue of $2.5 million, down from $3.55 million year-over-year. Net loss widened to $173.1 million ($1.39 per share) compared to $132.9 million ($1.24 per share) in the previous year. Total cash resources stood at $552.9 million as of December 31, 2024.